To test Cas9 / gRNA activity in goat primary fibroblasts, we designed six gRNAs
targeting myostatin (MSTN), nucleoporin 155 (NUP), prion protein (PrP), and beta - lactoglobulin (BLG), respectively (Figure 1A).
The finding that myostatin is not the sole regulator of muscle mass in mice raises the question as to whether
targeting myostatin alone will be the most effective strategy for manipulating this signaling pathway in humans.
Drugs
targeting myostatin could prove a godsend for people with muscle - wasting diseases such as muscular dystrophy.
Not exact matches
Now a scientist reports that mice engineered to make extra follistatin, which deactivates
myostatin, have four times the muscle of regular mice, suggesting a new
target for drugs to fight muscle - wasting diseases such as muscular dystrophy.
Myostatin has long been recognised as the body's major negative regulator of skeletal muscle mass, helping to maintain muscle homeostasis in the body, but creating molecules to
target all three related proteins together was a novel approach.
Because
myostatin normally acts to limit muscle growth, there has been considerable interest in
targeting this pathway to attempt to enhance muscle growth in human patients with muscle wasting and muscle degenerative diseases.
According to this model, local control of muscle growth would be achieved by regulating the extent to which the latent form of
myostatin is activated at the
target site, whereas global control of the metabolic homeostatic balance between muscle and other tissues would be achieved by regulating the size of the circulating pool of
myostatin.
Here, I show that overexpression of follistatin can also cause substantial muscle growth in mice lacking
myostatin, demonstrating that other TGF - ß related ligands normally cooperate with
myostatin to suppress muscle growth and that the capacity for enhancing muscle growth by
targeting this signaling pathway is much larger than previously appreciated.
Based on this finding, it appears that
myostatin can not be the sole
target for FLRG in the transgenic mice and, therefore, that additional ligands must be capable of suppressing muscle growth in vivo.
Myostatin, a member of the TGFβ superfamily of growth factors that is expressed primarily in skeletal muscle cells, is a genetically validated
target that regulates muscle mass.
• SRK - 015 specifically
targets the activation of latent forms of
myostatin and does not inhibit GDF11 or Activin A, proteins that are structurally similar to
myostatin but implicated in regulating a wide range of biological processes beyond muscle biology.
This one
targets follistatin levels in the body to reduce
myostatin actions.